SciGene Introduces New aCGH Training Course
News Oct 07, 2009
Participants learn how to prepare high quality fluorescently labeled gDNA then set up, hybridize and wash microarrays ready for analysis.
The innovative coursework provides improved methods for quality assessment and fragmentation of gDNA, fluorescent labeling/purification of DNA targets, preparation and loading of hybridization samples, and post-hybridization slide washing and drying.
Dr. Michael Herrler, Course Director, said, “We are excited to offer this innovative course for laboratories running or starting to run aCGH tests so they can improve test reliability and lower costs by discovering better methods to enhance microarray results and analyze clinical DNA samples”.
The course is held monthly at the Microarray Training Center in Sunnyvale, California. All participants receive a detailed training guide, reagent and equipment specifications for manual, partially automated and fully automated processing, a certificate of completion and array data on DVD for analyzed samples. Microarrays, reagents, labware and equipment are provided.
The first class starts November 3, 2009 with other classes scheduled for December 1, 2009 and January 5, 2010.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE